Cargando…

Screening for osteoporosis among post-menopausal women in community pharmacy

OBJECTIVES: To identify postmenopausal women with risk of osteoporosis through quantitative ultrasound imaging (QUI) and to value the medical intervention after the determination of the bone mineral density (BMD). METHODS: Cross-sectional descriptive study developed in a community pharmacy. During t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barris Blundell, Damià, Rodríguez Zarzuelo, Carmen, Sabio Sánchez, Belén, Gutiérrez álvarez, José Luis, Navarro Visa, Elena, Muñoz Valdés, Oscar, Garrido Jiménez, Belén, Gómez, Rocío Sánchez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166151/
https://www.ncbi.nlm.nih.gov/pubmed/25247006
_version_ 1782335217467392000
author Barris Blundell, Damià
Rodríguez Zarzuelo, Carmen
Sabio Sánchez, Belén
Gutiérrez álvarez, José Luis
Navarro Visa, Elena
Muñoz Valdés, Oscar
Garrido Jiménez, Belén
Gómez, Rocío Sánchez
author_facet Barris Blundell, Damià
Rodríguez Zarzuelo, Carmen
Sabio Sánchez, Belén
Gutiérrez álvarez, José Luis
Navarro Visa, Elena
Muñoz Valdés, Oscar
Garrido Jiménez, Belén
Gómez, Rocío Sánchez
author_sort Barris Blundell, Damià
collection PubMed
description OBJECTIVES: To identify postmenopausal women with risk of osteoporosis through quantitative ultrasound imaging (QUI) and to value the medical intervention after the determination of the bone mineral density (BMD). METHODS: Cross-sectional descriptive study developed in a community pharmacy. During the month of June of 2005 the community pharmacy enrolled postmenopausal women into the study. Women in treatment with calcium, vitamin D, hormone replacement therapy, estrogen receptor modulators, calcitonin or biphosphonates were considered criteria for exclusion. To all the women that consent to participate, the pharmacist measured BMD with the device Sahara Hologic Ultrasound Bone Densitometer at right calcaneus. Following the World Health Organization, women were classified as osteoporotic if their T-Score was less than -2.5 and as osteopenic if their T-Score ranged between -2.5 and -1.0. RESULTS: Of the 100 women screened, 11 (11%) presented risk of osteoporosis and 61 (61%) of osteopenia. The 18.5% postmenopausal women with body mass index lesser than 30 presented risk of osteoporosis and the 63.0% osteopenia. CONCLUSIONS: The QUI constitutes a useful tool in community pharmacy for the screening of osteoporosis and it supposes a greater integration of the community pharmacy within the health care.
format Online
Article
Text
id pubmed-4166151
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-41661512014-09-22 Screening for osteoporosis among post-menopausal women in community pharmacy Barris Blundell, Damià Rodríguez Zarzuelo, Carmen Sabio Sánchez, Belén Gutiérrez álvarez, José Luis Navarro Visa, Elena Muñoz Valdés, Oscar Garrido Jiménez, Belén Gómez, Rocío Sánchez Pharm Pract (Granada) Original Research OBJECTIVES: To identify postmenopausal women with risk of osteoporosis through quantitative ultrasound imaging (QUI) and to value the medical intervention after the determination of the bone mineral density (BMD). METHODS: Cross-sectional descriptive study developed in a community pharmacy. During the month of June of 2005 the community pharmacy enrolled postmenopausal women into the study. Women in treatment with calcium, vitamin D, hormone replacement therapy, estrogen receptor modulators, calcitonin or biphosphonates were considered criteria for exclusion. To all the women that consent to participate, the pharmacist measured BMD with the device Sahara Hologic Ultrasound Bone Densitometer at right calcaneus. Following the World Health Organization, women were classified as osteoporotic if their T-Score was less than -2.5 and as osteopenic if their T-Score ranged between -2.5 and -1.0. RESULTS: Of the 100 women screened, 11 (11%) presented risk of osteoporosis and 61 (61%) of osteopenia. The 18.5% postmenopausal women with body mass index lesser than 30 presented risk of osteoporosis and the 63.0% osteopenia. CONCLUSIONS: The QUI constitutes a useful tool in community pharmacy for the screening of osteoporosis and it supposes a greater integration of the community pharmacy within the health care. Centro de Investigaciones y Publicaciones Farmaceuticas 2006 2006-07-31 /pmc/articles/PMC4166151/ /pubmed/25247006 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Barris Blundell, Damià
Rodríguez Zarzuelo, Carmen
Sabio Sánchez, Belén
Gutiérrez álvarez, José Luis
Navarro Visa, Elena
Muñoz Valdés, Oscar
Garrido Jiménez, Belén
Gómez, Rocío Sánchez
Screening for osteoporosis among post-menopausal women in community pharmacy
title Screening for osteoporosis among post-menopausal women in community pharmacy
title_full Screening for osteoporosis among post-menopausal women in community pharmacy
title_fullStr Screening for osteoporosis among post-menopausal women in community pharmacy
title_full_unstemmed Screening for osteoporosis among post-menopausal women in community pharmacy
title_short Screening for osteoporosis among post-menopausal women in community pharmacy
title_sort screening for osteoporosis among post-menopausal women in community pharmacy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166151/
https://www.ncbi.nlm.nih.gov/pubmed/25247006
work_keys_str_mv AT barrisblundelldamia screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy
AT rodriguezzarzuelocarmen screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy
AT sabiosanchezbelen screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy
AT gutierrezalvarezjoseluis screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy
AT navarrovisaelena screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy
AT munozvaldesoscar screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy
AT garridojimenezbelen screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy
AT gomezrociosanchez screeningforosteoporosisamongpostmenopausalwomenincommunitypharmacy